These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 21254182)

  • 1. Endocannabinoids in liver disease.
    Tam J; Liu J; Mukhopadhyay B; Cinar R; Godlewski G; Kunos G
    Hepatology; 2011 Jan; 53(1):346-55. PubMed ID: 21254182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoids and their role in fatty liver disease.
    Mallat A; Lotersztajn S
    Dig Dis; 2010; 28(1):261-6. PubMed ID: 20460921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.
    Bátkai S; Mukhopadhyay P; Harvey-White J; Kechrid R; Pacher P; Kunos G
    Am J Physiol Heart Circ Physiol; 2007 Sep; 293(3):H1689-95. PubMed ID: 17557913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
    Pacher P; Haskó G
    Br J Pharmacol; 2008 Jan; 153(2):252-62. PubMed ID: 18026124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings.
    Mallat A; Teixeira-Clerc F; Deveaux V; Manin S; Lotersztajn S
    Br J Pharmacol; 2011 Aug; 163(7):1432-40. PubMed ID: 21457226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the endocannabinoid system in liver diseases.
    Caraceni P; Domenicali M; Giannone F; Bernardi M
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):65-77. PubMed ID: 19285261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.
    Osei-Hyiaman D; DePetrillo M; Pacher P; Liu J; Radaeva S; Bátkai S; Harvey-White J; Mackie K; Offertáler L; Wang L; Kunos G
    J Clin Invest; 2005 May; 115(5):1298-305. PubMed ID: 15864349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocannabinoids in liver disease and hepatic encephalopathy.
    Magen I; Avraham Y; Berry E; Mechoulam R
    Curr Pharm Des; 2008; 14(23):2362-9. PubMed ID: 18781986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders.
    Bisogno T; Di Marzo V
    CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):564-73. PubMed ID: 20632970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocannabinoids signaling: Molecular mechanisms of liver regulation and diseases.
    Wang M; Meng N; Chang Y; Tang W
    Front Biosci (Landmark Ed); 2016 Jun; 21(7):1488-501. PubMed ID: 27100518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.
    Kunos G; Tam J
    Br J Pharmacol; 2011 Aug; 163(7):1423-31. PubMed ID: 21434882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An introduction to the endocannabinoid system: from the early to the latest concepts.
    De Petrocellis L; Di Marzo V
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):1-15. PubMed ID: 19285257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications.
    Viveros MP; de Fonseca FR; Bermudez-Silva FJ; McPartland JM
    Endocr Metab Immune Disord Drug Targets; 2008 Sep; 8(3):220-30. PubMed ID: 18782018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver.
    Jeong WI; Osei-Hyiaman D; Park O; Liu J; Bátkai S; Mukhopadhyay P; Horiguchi N; Harvey-White J; Marsicano G; Lutz B; Gao B; Kunos G
    Cell Metab; 2008 Mar; 7(3):227-35. PubMed ID: 18316028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endocannabinoid system in chronic liver disease.
    Zamora-Valdés D; Ponciano-Rodríguez G; Chávez-Tapia NC; Méndez-Sánchez N
    Ann Hepatol; 2005; 4(4):248-54. PubMed ID: 16432489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice.
    Liu J; Zhou L; Xiong K; Godlewski G; Mukhopadhyay B; Tam J; Yin S; Gao P; Shan X; Pickel J; Bataller R; O'Hare J; Scherer T; Buettner C; Kunos G
    Gastroenterology; 2012 May; 142(5):1218-1228.e1. PubMed ID: 22307032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases.
    Pacher P; Gao B
    Am J Physiol Gastrointest Liver Physiol; 2008 Apr; 294(4):G850-4. PubMed ID: 18239059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: the endocannabinoid system in liver disease, a potential therapeutic target.
    Basu PP; Aloysius MM; Shah NJ; Brown RS
    Aliment Pharmacol Ther; 2014 Apr; 39(8):790-801. PubMed ID: 24612021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of the endocannabinoid system in cardiovascular disease.
    Pacher P; Steffens S
    Semin Immunopathol; 2009 Jun; 31(1):63-77. PubMed ID: 19357846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocannabinoids as novel mediators of liver diseases.
    Mallat A; Lotersztajn S
    J Endocrinol Invest; 2006; 29(3 Suppl):58-65. PubMed ID: 16751709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.